FDA Approves Updated Prescribing Information for Extended-Release ADHD Drug
Methylphenidate hydrochloride (Adhansia XR) was originally approved in 2019 for ADHD patients at least 6 years old. The US Food and Drug Administration (FDA) has approved updated prescribing information for methylphenidate hydrochloride (Adhansia XR) extended-release capsules CII as a treatment for attention deficit/hyperactivity disorder (ADHD).
Other Articles in this Edition
Drug relieves persistent daydreaming, fatigue, and brain sluggishness in adults with ADHD
Managing attention deficit disorder by training the brain
Participation in after-school activities decreases ADHD severity
FDA Approves Updated Prescribing Information for Extended-Release ADHD Drug
It’s game on for Akili as it launches digital campaign for first FDA-approved ADHD video game
Ending the mental health stigma in the tech community
What to do if a child with ADHD cannot sleep
Single people with ADHD describe what it’s like to date when your brain is wired differently
Increased risk of ADHD at short and long interpregnancy intervals in a national birth cohort